Clinical Trials · NCT02288377
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
- Phase
- Phase 2/Phase 3
- Recruitment status
- Terminated
- Sponsor
- Federation Francophone de Cancerologie Digestive
- Enrollment
- 53
- Start date
- Jan 2015
- Locations
- 24 sites, 4 countries
- Primary endpoint
- Proportion of Patients Alive and Progression-free at 6 Months